Key facts
- This page summarizes Christopher B. Ehrlich's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Oct 2024, 21:53.
Christopher B. Ehrlich - 25 Sep 2024 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)
- Reporting relationship
- Interim Chairman and CEO, Director
- Issuer ticker
- CERO
- Reported as of
- 25 Sep 2024
- Net transaction value
- -$275,000
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2024, 21:53:01 UTC
- Prior SEC filing
- 11 Jul 2024
- Next SEC filing
- 04 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher B. Ehrlich
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher B. Ehrlich filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 02 Oct 2024.
Change
- Previous filing in this sequence was filed on 11 Jul 2024.
- Current net transaction value: -$275,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CERO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,312,983
- Change %
- +1110%
- Price
- Shares after
- 5,791,808
- Date
- 25 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
CERO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,600
- Date
- 25 Sep 2024
- Ownership
- By Spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CERO
transaction
Derivative
Series A Convertible Preferred Stock
Options Exercise
- Transaction value
- $275,000
- Shares
- -275
- Change %
- -100%
- Price
- $1000.00
- Shares after
- 0
- Date
- 25 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,312,983
- Exercise price
- Footnotes
- F1
CERO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -572,182
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 30 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 572,182
- Exercise price
- $1.77
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date.
Footnote F2
Represents the forfeiture of employee stock options in connection with the Reporting Person's appointment as Chief Executive Officer of the Issuer.